The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
E. Daly, I. Turkoz, G. Salvadore, M. Fedgchin, D. Ionescu, H. Starr, S. Borentain, M. Trivedi, M. Thase, Jaskaran Singh
Depression and Anxiety July 22, 2021 DOI: 10.1002/da.23193 via Semantic Scholar
Summary
AI-generated from the abstractPatients with treatment-resistant depression who also have anxiety tend to respond less well to antidepressants. This analysis of existing trial data examined whether adding esketamine to an antidepressant improves outcomes for such patients. Among those with comorbid anxiety, the combination of esketamine and an antidepressant led to greater improvement in depressive symptoms compared to an antidepressant alone. The benefit was also seen in patients without anxiety, though the difference was less pronounced. The results suggest that esketamine augmentation may be particularly helpful for treatment-resistant depression patients who also struggle with anxiety.
Study at a glance
| Characteristics | Post hoc analysis Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression with or without comorbid anxiety |
| Interventions | Esketamine antidepressant |
| Keywords | Medicine Psychology |
| Key finding | Esketamine plus an antidepressant improved depressive symptoms more than an antidepressant alone in treatment-resistant depression patients with comorbid anxiety. |
Abstract
Comorbid anxiety is generally associated with poorer response to antidepressant treatment. This post hoc analysis explored the efficacy of esketamine plus an antidepressant in patients with treatment‐resistant depression (TRD) with or without comorbid anxiety.